GlassScriptPhysician profile
Roberto A Solis
NPI 1376650754
$13,420.33
in general payments reported to CMS, 2019-2025
46 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,607 · 2020: $1,288 · 2021: $1,006 · 2022: $465 · 2023: $2,502 · 2024: $3,068 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,888 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,888.39 |
| Education | $165.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,062.92 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $3,748.71 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.91 | 2019-2024 | Ofev, Spiriva Respimat |
| Philips North America LLC | $494.64 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genzyme Corporation | $453.09 | 2020-2025 | |
| Insmed, INC. | $412.42 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $361.01 | 2019-2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $353.47 | 2019-2020 | |
| Amgen INC. | $278.82 | 2023-2025 | Tezspire, Lumakras |
| Inspire Medical Systems, INC. | $272.54 | 2024-2025 | Inspire |
| Mylan Specialty L.P. | $267.80 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $223.41 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $212.61 | 2021-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $192.90 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $150.84 | 2023-2024 | Opsumit, Uptravi |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $143.89 | 2025 | Linx Reflux Management System |
| Grifols USA, LLC | $132.51 | 2021-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $121.11 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Merck Sharp & Dohme LLC | $96.07 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $81.28 | 2019-2025 | |
| Viatris Specialty LLC | $75.12 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $70.78 | 2019 | |
| Covis Pharma Gmbh | $65.30 | 2021-2022 | |
| Verona Pharma, INC. | $49.05 | 2025 | Ohtuvayre |
| Baxter Healthcare | $45.36 | 2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pharming Healthcare, INC. | $42.92 | 2022-2023 | Ruconest |
| Mallinckrodt Enterprises LLC | $40.20 | 2019 | |
| Lilly USA, LLC | $35.12 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $32.19 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $30.49 | 2020-2023 | Acthar |
| Abbvie INC. | $30.03 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $29.39 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.28 | 2019 | |
| Sanofi Pasteur INC. | $25.96 | 2019 | |
| Gilead Sciences, INC. | $24.88 | 2019 | |
| Optinose US, INC. | $23.89 | 2024 | |
| Shionogi INC | $19.50 | 2025 | Fetroja |
| Inari Medical, INC. | $17.26 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inogen, INC. | $16.79 | 2025 | |
| Masimo Corporation | $16.26 | 2024 | Sedline |
| Paratek Pharmaceuticals, INC. | $15.38 | 2023 | Nuzyra |
| Axsome Therapeutics, INC. | $14.20 | 2023 | Sunosi |
| Pharmacosmos Therapeutics INC. | $13.92 | 2022 | |
| Itamar Medical INC | $13.00 | 2023 | Watchpatone |
| Teva Pharmaceuticals USA, INC. | $12.10 | 2021 | |
| Circassia INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.